On October 5, 2023, the Office of Research Integrity (ORI) of the Department of Health and Human Services (HHS) issued a notice of proposed rulemaking to update the Public Health Service (PHS) Policies on Research Misconduct (the Proposed Rule), which set forth the requirements for addressing research misconduct in PHS-funded research. Many types of institutions
Latest Post
More Posts
Clinical Trials: Consent Process Clarified in New FDA Final Guidance
Decentralized Clinical Trials: Sponsor Responsibilities
Decentralized Clinical Trials: Investigator Responsibilities
Key Takeaways from the FDA’s First Draft Guidance on Clinical Trials with Psychedelic Drugs
Decentralized Clinical Trials Blog Series
Episode 24: The Rules Have Changed: Decentralized Clinical Trials for Drugs
FDA’s New Guidance Proposes Flexible Use of AI in Medical Devices
FDA Encourages the Use of Decentralized Clinical Trials in New Draft Guidance
COVID-19 Related Medical Devices: FDA Finalizes Transition Plan Guidance
Subscribe: Subscribe via RSS
Blogs
Firm/Org